----item----
version: 1
id: {E3FFEB27-1F55-46BC-BBA3-A75B80001E74}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/14/Celgene buys stake in Mesoblast
parent: {A8A43D63-6ACC-4DA4-B2AE-AFEB13F96A43}
name: Celgene buys stake in Mesoblast
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: b124d33e-2c36-4946-81f8-aa234258f495

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 31

Celgene buys stake in Mesoblast
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 31

Celgene buys stake in Mesoblast
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1610

<p>Celgene has agreed to buy a minority stake in Australian regenerative therapy firm Mesoblast, shelling out Aus$58.5m (US$45m) for 15.3 million shares, or around 4.8% of outstanding stock. The deal values Mesoblast's stock at Aus$3.82 per share, a 19% premium over its closing price of Aus$3.21 on 10 April, the last trading day before the transaction was announced. The firm's share price closed up 24% at Aus$3.99 on 13 April.</p><p>The agreement also gives Celgene a six-month right of first refusal for Mesoblast's stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.</p><p>Mesoblast's "off-the-shelf" stem cell products are being developed for various indications including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions. The company says it has five products in Phase III trials or that are Phase III ready, and believes it will have the first industrially manufactured allogeneic stem cell products approved in Japan and the US.</p><p>The lead candidates in development include MPC-150-IM for chronic congestive heart failure (being developed with Teva Pharmaceutical Industries), MPC-06-ID for chronic discogenic low back pain, MSC-100-IV for acute GVHD, and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy.</p><p>In addition, one product, JR-031, has been submitted for regulatory approval in Japan for acute GVHD, by partner JCR Pharmaceuticals.</p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 434

<p>Celgene has agreed to buy a minority stake in Australian regenerative therapy firm Mesoblast, shelling out Aus$58.5m (US$45m) for 15.3 million shares, or around 4.8% of outstanding stock. The deal values Mesoblast's stock at Aus$3.82 per share, a 19% premium over its closing price of Aus$3.21 on 10 April, the last trading day before the transaction was announced. The firm's share price closed up 24% at Aus$3.99 on 13 April.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 31

Celgene buys stake in Mesoblast
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150414T050000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150414T050000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150414T050000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028422
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 31

Celgene buys stake in Mesoblast
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{6B0DE3A8-39EC-48B6-800A-BA8DAF5799A4}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357775
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042329Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

b124d33e-2c36-4946-81f8-aa234258f495
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042329Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
